Thrombosis and Haemostasis CHIP and atherothrombotic risk

A. Murphy,D. Dragoljevic,P. Natarajan,Nan Wang

2022-01-01

Abstract:: Haematopoiesis is the process of blood production, essential for the continued supply of immune cells and red blood cells. However, the proliferative nature of haematopoietic stem cell (HSCs) renders them susceptible to developing somatic mutations. HSCs carrying a mutation can gain a selective advantage compared to normal HSCs and result in haematological disorders. One such disorder is termed clonal haematopoiesis of indeterminate potential (CHIP), a pre-malignant state associated with ageing, where the mutant HSCs are responsible for producing a small portion of the mature immune cells in the circulation and subsequently in tissues. People with CHIP have been shown to have an increased risk of mortality due to cardiovascular disease (CVD). Why this occurs is under rigorous investigation, but the majority of the studies to date suggest increased atherosclerosis is due to heightened inflammatory cytokine release from mutant lesional macrophages. However, given CHIP is driven by several mutations, other haematopoietic lineages can be altered to promote CVD. In this review we explore the relationship between mutations in genes causing CHIP and atherothrombotic disorders, along with potential mechanisms of enhanced clonal outgrowth and potential therapies and strategies to slow CHIP progression. Abstract Haematopoiesis is the process of blood production, essential for the continued supply of immune cells and red blood cells. However, the proliferative nature of haematopoietic stem cell (HSCs) renders them susceptible to developing somatic mutations. HSCs carrying a mutation can gain a selective advantage compared to normal HSCs and result in haematological disorders. One such disorder is termed clonal haematopoiesis of indeterminate potential (CHIP), a pre-malignant state associated with ageing, where the mutant HSCs are responsible for producing a small portion of the mature immune cells in the circulation and subsequently in tissues. People with CHIP have been shown to have an increased risk of mortality due to cardiovascular disease (CVD). Why this occurs is under rigorous investigation, but the majority of the studies to date suggest increased atherosclerosis is due to heightened inflammatory cytokine release from mutant lesional macrophages. However, given CHIP is driven by several mutations, other haematopoietic lineages can be altered to promote CVD. In this review we explore the relationship between mutations in genes causing CHIP and atherothrombotich disorders, along with potential mechanisms of enhanced clonal outgrowth and potential therapies and strategies to slow CHIP progression.